Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Ruiyuan Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4786-6330; OpenAlex author ID A5082815201. Sources: OpenAlex.

Their work

Papers
15 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2020: 1 paper · 2021: 4 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers

Papers 15

  1. Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217162↗
  2. Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer. Co-author DOI 10.1097/jp9.0000000000000175↗
  3. Early Detection of Pancreatic Cancer: Considerable Advances, but Still a Long Way to Go Co-author DOI 10.1016/j.cgh.2023.08.022↗
  4. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway. Co-author DOI 10.1038/s41419-023-05987-7↗
  5. Cell-in-Cell-Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer. First author DOI 10.1053/j.gastro.2023.08.035↗
  6. A commentary on ‘Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection’ Co-author DOI 10.1097/js9.0000000000000633↗
  7. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. First author DOI 10.1002/cac2.12360↗
  8. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09927-0↗
  9. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in … Co-author DOI 10.1186/s12885-022-09983-6↗
  10. Prognostic value of glycolysis markers in pancreatic cancer: A systematic review and meta-analysis. First author DOI 10.3389/fonc.2022.1004850↗
  11. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. First author DOI 10.1002/cac2.12204↗
  12. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. First author DOI 10.1186/s12935-021-01928-6↗
  13. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Co-author DOI 10.1186/s13045-021-01131-0↗
  14. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2021.758004↗
  15. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Co-author DOI 10.3389/fonc.2020.572722↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yupei Zhao · 12 shared papers, 2020–2024 · strength 2.32
  2. Jianlu Song · 10 shared papers, 2021–2024 · strength 1.81
  3. Rexiati Ruze · 10 shared papers, 2021–2024 · strength 1.81
  4. Yuan Chen · 10 shared papers, 2020–2024 · strength 1.68
  5. Xinpeng Yin · 8 shared papers, 2022–2024 · strength 1.52
  6. Chengcheng Wang · 6 shared papers, 2021–2024 · strength 1.17
  7. Chengcheng Wang · 3 shared papers, 2021–2023 · strength 0.59
  8. Jinshou Yang · 4 shared papers, 2020–2021 · strength 0.53
  9. Lei You · 4 shared papers, 2020–2021 · strength 0.53
  10. Qiang Xu · 3 shared papers, 2022 · strength 0.50
  11. Chengcheng Wang · 2 shared papers, 2023–2024 · strength 0.43
  12. Chengcheng Wang · 2 shared papers, 2022–2023 · strength 0.35
  13. Bo Ren · 2 shared papers, 2020–2021 · strength 0.24
  14. Gang Yang · 2 shared papers, 2020–2021 · strength 0.24
  15. Hui Zhang · 1 shared paper, 2023 · strength 0.18
  16. Qiang Xu · 1 shared paper, 2022 · strength 0.17
  17. Jiangdong Qiu · 1 shared paper, 2021 · strength 0.16
  18. Bo Xu Ren · 1 shared paper, 2021 · strength 0.16
  19. Taiping Zhang · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.